OBJECTIVE To evaluate the relative bioavailibility and bioequivalence of paroxetine hydrochloride film-coated tablets. METHODS In a randomized crossover study， 24 healthy Chinese male subjects received a single oral dose (20 mg) of either test or reference paroxetine hydrochloride tablets after an overnight fast. The plasma concentrations of paroxetine were determined by a validated LC-MS/MS method. The pharmacokinetic parameters， the relative bioavailability and bioequivalence of two formulations were evaluated by DAS 2.0 software. RESULTS After a single oral dose of 20 mg test or reference paroxetine tablets， the pharmacokinetic parameters of paroxetine were as follows： ρ_max (5.102±2.955) and (5.396±2.852) μg·L^-1； t_max (5.22±1.83) and (5.35±0.78) h ； t_{1 /2} (11.76±2.91) and (11.98±3.57) h； AUC_{0~96 h} (118.1±90.2) and (118.9±86.0) μg·h·L^-1； AUC_0-∞ (120.2±91.0) and (121.5±87.6) μg·h·L^-1， respectively. CONCLUSION The relative bioavailability of the test paroxetine hydrochloride film-coated tablets is (100.6±22.0)% . The two preparations are bioequivalent.